Richard Carvajal, MD

Richard Carvajal, MD

Deputy Physician-in-Chief and Director of Medical Oncology
Roy J. and Tara Zuckerberg Professor in Medical Oncology
Northwell Health Cancer Institute
Lake Success, NY

Related Videos

What was it about cytokine-based treatments targeting the IL-2 pathway that suggested they had potential to provide immune system-directed treatment where other therapies had failed? And how did the results from ARTISTRY-1 inform your analysis? Video

What was it about cytokine-based treatments targeting the IL-2 pathway that suggested they had potential to provide immune system-directed treatment where other therapies had failed? And how did the results from ARTISTRY-1 inform your analysis?

Against this backdrop of positive signals for mucosal melanoma observed in ARTISTRY-1, and confirmation that nemvaleukin could be managed effectively and safely in the outpatient environment, how did you approach the design of ARTISTRY-6? Video

Against this backdrop of positive signals for mucosal melanoma observed in ARTISTRY-1, and confirmation that nemvaleukin could be managed effectively and safely in the outpatient environment, how did you approach the design of ARTISTRY-6?

After taking note of the signals for response in mucosal melanoma that were reported in ARTISTRY-1, how did you proceed with the design for ARTISTRY-6 evaluating the efficacy and safety of this novel cytokine fusion protein in mucosal melanoma? Video

After taking note of the signals for response in mucosal melanoma that were reported in ARTISTRY-1, how did you proceed with the design for ARTISTRY-6 evaluating the efficacy and safety of this novel cytokine fusion protein in mucosal melanoma?

What was it about the novel, engineered cytokine fusion protein nemvaleukin that led you to revisit the IL-2-mediated therapeutic space in search of a treatment that would overcome previous limitations with high dose human recombinant IL-2? Video

What was it about the novel, engineered cytokine fusion protein nemvaleukin that led you to revisit the IL-2-mediated therapeutic space in search of a treatment that would overcome previous limitations with high dose human recombinant IL-2?

On the basis of what early clinical data, safety profile, and mechanistic features does the FDA typically approve a drug such as nemvaleukin for fast track designation? Video

On the basis of what early clinical data, safety profile, and mechanistic features does the FDA typically approve a drug such as nemvaleukin for fast track designation?

Can you provide an overview of the landscape of immunotherapy for melanoma and its rarer subtypes, with an emphasis on the role of immune checkpoint inhibition, its limitations, and the need for additional immuno-oncology-focused co-therapies? Video

Can you provide an overview of the landscape of immunotherapy for melanoma and its rarer subtypes, with an emphasis on the role of immune checkpoint inhibition, its limitations, and the need for additional immuno-oncology-focused co-therapies?

Moving beyond investigation of nemvaleukin in mucosal melanoma and/or other rare tumor types, how might the cancer immunotherapy community think about advancing studies of nemvaleukin across a wider taxonomy of tumor subtypes? Video

Moving beyond investigation of nemvaleukin in mucosal melanoma and/or other rare tumor types, how might the cancer immunotherapy community think about advancing studies of nemvaleukin across a wider taxonomy of tumor subtypes?

Based on current I-O approaches to managing mucosal melanoma, why does this refractory variant of melanoma represent a good model for studying the efficacy and safety of a novel, engineered cytokine fusion protein such as nemvaleukin? Video

Based on current I-O approaches to managing mucosal melanoma, why does this refractory variant of melanoma represent a good model for studying the efficacy and safety of a novel, engineered cytokine fusion protein such as nemvaleukin?

What is it about nemvaleukin’s novel engineering, mechanism-of-action (MOA), as well as its manageable safety profile, that makes it unique among novelly generated cytokines that have been developed in the cancer immunotherapy space? Video

What is it about nemvaleukin’s novel engineering, mechanism-of-action (MOA), as well as its manageable safety profile, that makes it unique among novelly generated cytokines that have been developed in the cancer immunotherapy space?